Equip WNV (previously Duvaxyn WNV)

RSS

adjuvanted vaccine against West Nile virus in horses

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European Public Assessment Report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 10/04/2017

Authorisation details

Product details
Name
Equip WNV (previously Duvaxyn WNV)
Agency product number
EMEA/V/C/000137
Active substance
inactivated West Nile virus, strain VM-2
International non-proprietary name (INN) or common name
adjuvanted vaccine against West Nile virus in horses
Species
Horses
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI05AA10
Publication details
Marketing-authorisation holder
Zoetis Belgium SA
Revision
13
Date of issue of marketing authorisation valid throughout the European Union
20/11/2008
Contact address
Rue Laid Burniat 1
1348 Louvain-la-Neuve
Belgium

Product information

22/03/2017 Equip WNV (previously Duvaxyn WNV) - EMEA/V/C/000137 - IG/0747

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

IMMUNOLOGICALS FOR EQUIDAE

Therapeutic indication

For the active immunisation of horses of six months of age or older against West-Nile-virus disease by reducing the number of viraemic horses.

Assessment history

How useful was this page?

Add your rating